Cancer patients receiving stable doses of TTS FE or TTS BU can be safely switched to the alternative transdermal opioid.
Eligible participants will be receiving stable mono- or dual therapy with metformin, sulfonylurea, or pioglitazone, or insulin alone or in combination with metformin.
A prospective "N of 1" study was carried out in a sample of volunteers with cancer pain receiving stable doses of TTS FE or TTS BU, with adequate pain and symptom control.
A total of 1,008 French hemodialysis and peritoneal dialysis patients receiving stable rHuEPO therapy by either the intravenous (i.v., N = 217) or subcutaneous (s.c., N = 791) route were switched to darbepoetin alfa given by the same route of administration at a reduced dosing frequency.
HIV-infected volunteers receiving stable ART with plasma HIV-1 RNA<50 copies/ml and a CD4 count of >300/µl for at least 6 months were studied.
[17] ACTG 5102 enrolled HIV-1-infected adults receiving stable ART, who were virologically fully suppressed (<200 HIV RNA copies/mm3) for at least three months at the time of enrollment and had a CD4 cell count ≥500 cells/mm3.
Briefly, inclusion criteria were as follows: patients treated at CD4 cell count >350/µL and plasma viral load (VL <50,000 copies/ml, receiving stable ART within 6 months prior to inclusion with no more than one prior treatment failure and exhibiting, at baseline, CD4 cell count >450/µL and stable VL <5000 copies/mL.
Selection was restricted to patients receiving stable treatment with donepezil 10 mg/day.
Studies where participants are receiving stable migraine prophylactic treatment will be included.
In the S-14Y group 15 were receiving stable doses of antipsychotic medication.
Individuals receiving stable doses of cholinesterase-inhibitor drugs or memantine were included.
